Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: Life Sci. 2016 Feb 17;159:90–96. doi: 10.1016/j.lfs.2016.02.067

Fig. 2. Linagliptin treatment reduces contractile response to ET-1 in basilar arteries from both diabetic and non-diabetic rats.

Fig. 2

Basilar arteries harvested from rats from each group were mounted on a DMT wire myograph for assessment of vascular function. (A). Dose response curves to ET-1 in Nondiabetic, Nondiabetic+Linagliptin, Diabetic, and Diabetic+Linagliptin were performed. (B). Diabetic arteries exhibited an increase in maximum contractile response compared to Nondiabetic arteries, and linagliptin treatment reduced this response in each group. (C). Total contraction response was improved in the diabetic group following treatment with linagliptin. (D) There was no statistically significant difference in sensitivity to ET-1 among the groups. Contractile response expressed as % increase from baseline and the results are given as mean ± SEM, n=3–5, *=p<0.05 vs. Nondiabetic, #=p<0.05 vs. Diabetic)